AVEO Pharmaceuticals, Inc. (AVEO)

[Biotech Pharmer]

With Tivo approved in Europe and an ongoing new US trial that the FDA supplied input on, the odds of 2018 FDA approval are now much better than they were 4 months ago. BMY has its eyes on the Tinivo trial closely as it progresses through P2. The NVS/AV-380 partnership is proceeding, as NVS paid $1.8M for more product back in the 1st quarter. Then there's Ficla, and then there's AV-353. I believe a fair value is $2.5B for AVEO's whole bag of tricks. $2.5B / 118M shares puts a realistic value of $21+ per share. JMO.
Do your own DD.